LU508014B1 - BIONIC DRUG-LOADED NANOPARTICLE EXPRESSING CXCR4, AND PREPARATION METHOD THEREFOR AND USE THEREOF - Google Patents

BIONIC DRUG-LOADED NANOPARTICLE EXPRESSING CXCR4, AND PREPARATION METHOD THEREFOR AND USE THEREOF Download PDF

Info

Publication number
LU508014B1
LU508014B1 LU508014A LU508014A LU508014B1 LU 508014 B1 LU508014 B1 LU 508014B1 LU 508014 A LU508014 A LU 508014A LU 508014 A LU508014 A LU 508014A LU 508014 B1 LU508014 B1 LU 508014B1
Authority
LU
Luxembourg
Prior art keywords
drug
loaded nanoparticle
msc
bionic
cell membrane
Prior art date
Application number
LU508014A
Other languages
English (en)
French (fr)
Inventor
Lingyun Sun
Dagan Zhang
Jingjing Gan
Yuanjin Zhao
Junyi Che
Original Assignee
Nanjing Drum Tower Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Drum Tower Hospital filed Critical Nanjing Drum Tower Hospital
Application granted granted Critical
Publication of LU508014B1 publication Critical patent/LU508014B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)

Claims (10)

BL-5900 Ansprüche LU508014
1. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4, dadurch gekennzeichnet, dass es Folgendes umfasst: Milchsäure-Glykolsäure-Copolymer und Immunsuppressivum werden in einem bestimmten Verhältnis gemischt und die Mikrofluidik-Technologie wird verwendet, um die mit Arzneistoffen beladenen Nanopartikeln herzustellen; MSC-Zellen in der stabilen Expresson von CXCR4-Membranprotein werden hergestellt, um die Zellmembran zu extrahieren und die manipulierte Stammzellmembran zu erhalten; und die Fusion von manipulierten Stammzellmembranen und mit Arzneistoffen beladenen Nanopartikeln wird durchgeführt, um die mit bionischen Arzneistoffen beladenen Nanopartikeln in der Expression von CXCR4 zu erhalten, wobei die mit bionischen Arzneistoffen beladenen Nanopartikeln in der Expression von CXCR4 mit Arzneistoffen beladenen Nanopartikeln für bionische Zellmembranen mit chemotaktischen Eigenschaften sind; wobei die Methode für die Fusion der manipulierten Stammzellmembran und der mit Arzneistoffen beladenen Nanopartikeln darin besteht, die manipulierte Stammzellmembran und die mit Arzneistoffen beladenen Nanopartikeln in einem Massenverhältnis von 0,8-1:0,8-1 zu mischen und durch Ultraschall die Fusion durchzuführen, wobei die Ultraschallbehandlungsfrequenz 10 bis 30 kHz, die Zeit 30 bis 60 s und die Temperatur 5 bis 10 °C beträgt.
2. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4 nach Anspruch 1, dadurch gekennzeichnet, dass das Immunsuppressivum aus mindestens einem von Cyclosporin, Methotrexat und Cyclophosphamid ausgewählt wird.
3. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4 nach Anspruch 1, dadurch gekennzeichnet, dass Milchsäure- Glykolsäure-Copolymer und Immunsuppressivum in einem Massenverhältnis von 5 bis 10:1 gemischt werden.
4. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der 1
BL-5900 Expression von CXCR4 nach Anspruch 1, dadurch gekennzeichnet, dass das spezifische 0508014 Verfahren zur Herstellung von mit Arzneistoffen beladenen Nanopartikeln durch die Mikrofluidik-Technologie darin besteht, Milchsäure-Glykolsäure-Copolymer und Immuninhibitor zu mischen und in Dimethylsulfoxid zu lösen, um ein Wasserphasengemisch zu bilden, wobei das Masse/Volumen-Verhältnis von Milchsäure- Glykolsäure-Copolymer und Immunsuppressivum zu Dimethylsulfoxid 5-15:1 mg/ml beträgt, wobei das Wasserphasengemisch in hochreines Wasser getropft wird, wobei das Volumenverhältnis von Reinstwasser zum Wasserphasengemisch 6—10:1 beträgt und es für 0,5-3 Stunden bei Raumtemperatur gerührt wird.
5. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4 nach Anspruch 1, dadurch gekennzeichnet, dass die MSC-Zellen aus mindestens einer Art von menschlichen Nabelschnur-MSC-Zellen, menschlichen Fett-MSC-Zellen oder menschlichen Knochenmark-MSC-Zellen ausgewählt werden.
6. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4 nach Anspruch 1, dadurch gekennzeichnet, dass das Herstellungsverfahren für MSC-Zellen in der Expression von CXCR4-Membranprotein darin besteht, die MSC-Zellen der P3-Generation zu kultivieren, bis die Fusion 80-90 % erreicht, wobei nach der Transfektion von MSC-Zellen mit dem Medium, das Lv-CXCR4- Uberexpressions-Lentivirus enthält, DMEM-Medium verwendet wird, um das Medium zu ersetzen, das Lv-CXCR4 iberexprimierendes Lentivirus enthält, wonach die Kultivierung forgesetzt wird und dann ein Resistenzscreening durchgeführt wird, um die MSC-Zellen für eine stabile Expression von CXCR4-Membranprotein zu erhalten.
7. Herstellungsverfahren für mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4 nach Anspruch 1, dadurch gekennzeichnet, dass die Zellmembran lysiert wird, um die Zellmembran zu extrahieren, wobei das Verfahren zur Gewinnung der manipulierten Stammzellmembran darin besteht, die Zellen mit vorgekühltem Phosphatpufferlôsung zu spülen und in hypotonischer Lyselôsung zu resuspendieren, wonach sie in flüssigen Stickstoff gegeben und wiederholt eingefroren und aufgetaut werden, um die Zellen vollständig zu lysieren und das Zellmembranpellet zentrifugal zu extrahieren, wonach sie in phosphatgepufferter Kochsalzlôsung resuspendiert und 2
BL-5900 . . y LU508014 wiederholt extrudiert werden, um manipulierte Stammzellmembranen zu erhalten .
8. Mit bionischen Arzneistoffen beladene Nanopartikeln in der Expression von CXCR4, die mit dem Verfahren nach einem der Anspriiche 1 bis 7 hergestellt werden.
9. Anwendung der mit bionischen Arzneistoffen beladenen Nanopartikeln nach Anspruch 8 zur Herstellung von immunsuppressiven Arzneimitteln.
10. Anwendung nach Anspruch 9, dadurch gekennzeichnet, dass die Anwendung der mit bionischen Arzneistoffen beladenen Nanopartikeln zur Herstellung von Arzneimitteln zur Verabreichung gegen rheumatoide Arthritis. 3
LU508014A 2024-01-25 2024-08-16 BIONIC DRUG-LOADED NANOPARTICLE EXPRESSING CXCR4, AND PREPARATION METHOD THEREFOR AND USE THEREOF LU508014B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410101360.4A CN117919205A (zh) 2024-01-25 2024-01-25 一种表达cxcr4的仿生载药纳米粒子及其制备方法和应用

Publications (1)

Publication Number Publication Date
LU508014B1 true LU508014B1 (en) 2025-02-17

Family

ID=90769867

Family Applications (1)

Application Number Title Priority Date Filing Date
LU508014A LU508014B1 (en) 2024-01-25 2024-08-16 BIONIC DRUG-LOADED NANOPARTICLE EXPRESSING CXCR4, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Country Status (3)

Country Link
CN (1) CN117919205A (de)
LU (1) LU508014B1 (de)
WO (1) WO2025156581A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117257762A (zh) * 2023-09-26 2023-12-22 中国药科大学 一种工程化干细胞膜仿生制剂及其制备方法和应用
CN117919205A (zh) * 2024-01-25 2024-04-26 南京鼓楼医院 一种表达cxcr4的仿生载药纳米粒子及其制备方法和应用
CN118576569B (zh) * 2024-05-07 2025-04-01 扬州大学 一种具有靶向缓释功能的纳米细胞药物及其在骨质疏松治疗中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111265549B (zh) * 2020-03-02 2022-03-01 苏州大学 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
CN111588705B (zh) * 2020-05-29 2022-07-05 复旦大学附属华山医院 一种间充质干细胞膜伪装磁性载药纳米颗粒及其制备方法和应用
CN114470223B (zh) * 2022-01-13 2023-09-29 苏州大学 清除促炎因子和抑制t细胞活化的细胞膜包被纳米诱饵及其制备方法与应用
CN116139101B (zh) * 2023-01-12 2024-03-22 浙江大学 一种特异性靶向肺部炎症组织的工程化间充质干细胞仿生柔性脂质体及其制备方法和应用
CN117143821A (zh) * 2023-07-13 2023-12-01 中国人民解放军总医院第八医学中心 一种过表达cxcr7的间充质干细胞及其构建方法与应用
CN117919205A (zh) * 2024-01-25 2024-04-26 南京鼓楼医院 一种表达cxcr4的仿生载药纳米粒子及其制备方法和应用

Also Published As

Publication number Publication date
CN117919205A (zh) 2024-04-26
WO2025156581A1 (zh) 2025-07-31

Similar Documents

Publication Publication Date Title
LU508014B1 (en) BIONIC DRUG-LOADED NANOPARTICLE EXPRESSING CXCR4, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Yu et al. Cell-mediated targeting drugs delivery systems
He et al. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application
Bush et al. Biological cells as therapeutic delivery vehicles
Sheets et al. Developing implantable scaffolds to enhance neural stem cell therapy for post-operative glioblastoma
WO2021174738A1 (zh) 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
Colton Engineering challenges in cellencapsulation technology
Li et al. Advanced generation therapeutics: biomimetic nanodelivery system for tumor immunotherapy
Shen et al. Nano/genetically engineered cells for immunotherapy
Attia et al. Mesenchymal stem cells: the past present and future
WO2018017879A1 (en) Zwitterionic microgels, their assemblies and related formulations, and methods for their use
Shin et al. Stem cell mimicking nanoencapsulation for targeting arthritis
AU2023206197B2 (en) Enhanced multipotent cells and microvascular tissue and methods of use thereof
CA2455726A1 (en) Treatment of muscular dystrophy with cord blood cells
Deshmukh et al. Extracellular nanovesicles: from intercellular messengers to efficient drug delivery systems
Tian et al. Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis
CN116370647B (zh) 一种用于胰腺癌免疫治疗的工程化外泌体及制备方法
Fan et al. Adoptive macrophages suppress glioblastoma growth by reversing immunosuppressive microenvironment through programmed phenotype repolarization
CN113398092A (zh) 一种膀胱靶向载药外泌体及应用和治疗膀胱疾病药物
CN120550094B (zh) 一种三元共修饰的工程化鹿茸MSCs外泌体及其制备方法和应用
Moise et al. Assessing the immunosuppressive activity of alginate-encapsulated mesenchymal stromal cells on splenocytes
CN106632688A (zh) 一种用于修饰微泡的多肽以及靶向gbm的药物制剂
CN113893352B (zh) 一种jo蛋白锚定的载药免疫细胞及其制备方法和应用
CN120519365B (zh) 用于药物递送载体的细菌的制备方法及其用途
LU508180B1 (en) System for targeted delivery of amlodipine drug, method for preparing same and application thereof

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20250217